Q-omics provides the consensus-scored ZNF396 profile across patient tissues and cancer cell-line models. ZNF396 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, ZNF396 is differentially expressed in 10, with the highest sampling consensus in THCA. Additionally, ZNF396 RNA expression shows 20,357 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, THCA, and UVM as cancer lineages where ZNF396 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF396 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF396 survival associations across molecular data types. ZNF396 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF396 RNA expression–survival associations across cancer types. High ZNF396 expression shows unfavorable associations in LGG, but favorable associations in KIRC, KIRP, BRCA, LUAD and HNSC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for ZNF396 RNA expression.
This table summarizes ZNF396 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for ZNF396. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF396 shows lower tumor expression in THCA, KICH, COAD and LUSC and higher tumor expression in LIHC and CHOL. The THCA box plot shows higher ZNF396 RNA expression in normal versus tumor tissue (log2 FC = −1.265, t-test p < 0.001).
This table shows molecular features associated with ZNF396 in patient tissues and cancer cell lines. In patient samples, ZNF396 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, ZNF396 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in URINARY_TRACT and BREAST.
